Breaking AI & Tech News Analyzed

For the first time, thousands of cancer patients from Black and minority ethnic backgrounds will benefit from an enhanced genetic test offered by the NHS. The new screening expands the panel of DPYD gene variants from four to five, directly addressing a long‑standing bias that left non‑white patients vulnerable to dangerous chemotherapy side‑effects. In England, patients slated for chemotherapy undergo a genetic check that can guide dose adjustments and mitigate adverse reactions such as mouth sores, hair loss, nausea, fatigue, and, in severe cases, death. Up to 40% of the 38,000 individuals receiving fluoropyrimidine‑based chemotherapy each year experience a harmful drug reaction. Previously, the test only targeted four DPYD variants common in people of European descent, meaning many Black patients received inaccurate “all‑clear” results. The addition of a fifth variant—more prevalent among African, Caribbean and other minority groups—means clinicians can now identify patients at risk who were previously missed. Since its rollout at Manchester University NHS Foundation Trust last September, three minority‑ethnic patients have had their initial chemotherapy doses adjusted, lowering their chance of a potentially fatal reaction. Dr Veline L’Esperance, senior clinical adviser at the NHS Race and Health Observatory, called the change “tangible results for patients who have historically been left behind.” She emphasized that the update shifts the discussion on ethnic health inequality from rhetoric to actionable care. Prof Habib Naqvi, chief executive of the NHS Race and Health Observatory, described the development as a “groundbreaking outcome” for chemotherapy safety, while noting that ethnic minorities remain under‑represented in genomic research and biobanks. He warned that broader inclusion is essential for the promised benefits of precision medicine to reach all communities. Prof Dame Sue Hill, chief scientific officer for NHS England, highlighted the significance of discovering the fifth variant: “Personalising chemotherapy based on genetics can save lives and reduce harmful side‑effects, especially for patients of African ancestry.” She added that the North West NHS Genomic Medicine Service has already demonstrated the practical impact of this approach. These steps come amid broader evidence that minority patients in the UK face longer diagnostic waits, more GP visits before a cancer diagnosis, and lower perceived support during treatment. The expanded DPYD test represents a concrete effort to close those gaps and ensure equitable, science‑driven care for all cancer patients.

Euphoria's third season has been a long-awaited return, but unfortunately, it's absolutely not worth the wait. The show's creator, Sam Levinson, has taken a darker and more desperate approach, focusing on the characters' bleak lives and struggles with sex work, drugs, and trauma.The season picks up five years after the end of season two, with recovering addict Rue (Zendaya) drawn into the world of drug dealer Laurie (Martha Kelly). Her life as a mule between Mexico and the US is depicted in gritty and intense cinematic sequences, drawing on westerns and blaxploitation.Meanwhile, Cassie (Sydney Sweeney) is on the cusp of trad wifedom with toxic jock Nate (Jacob Elordi), but their relationship is marred by Nate's crumbling business and Cassie's OnlyFans content. The show's handling of her cam girl ambitions feels bafflingly dated and voyeuristic.The performances are mostly good, with standout performances from Zendaya, Sweeney, and Adewale Akinnuoye-Agbaje. However, the show's grim and humorless tone makes it feel like a chore to watch.Levinson's approach to exploring the devastating impact of synthetic opioids on ordinary Americans feels heavy-handed and desperate. The show's focus on brainrot bimbo-ism and male perversion also detracts from its once unapologetically queer heart.Overall, Euphoria season three is a disappointing and grubby addition to the series, feeling like a contractual obligation rather than a passion project.

Britney Spears, one of the most iconic pop artists in US history, has taken a significant step towards recovery by voluntarily entering a rehabilitation centre after her arrest in March for driving under the influence (DUI). The arrest occurred in Ventura County, California, where Spears was stopped by police for driving erratically. The tests revealed the presence of drugs and alcohol in her system, leading to her brief detention. Her manager at the time described her actions as 'completely inexcusable' and emphasized that Spears would take the necessary steps to comply with the law and make overdue changes in her life. This recent development marks another chapter in Spears' journey, which has seen her step back from her music career in recent years. Her last album was released in 2016, and her most recent chart success was in 2022 with 'Hold Me Closer,' a collaboration with Elton John that reached the US and UK Top 10. In 2024, Spears expressed her intention to never return to the music industry, stating a preference for ghostwriting for other artists. Additionally, in January, she mentioned that she would never perform again in the US, though she hoped to perform in the UK and Australia. Spears has also made headlines with her memoir, 'The Woman in Me,' published in 2023, which is currently being adapted for the big screen. Her career has not been without challenges, including a conservatorship arrangement in 2008 that lasted until 2021, which significantly impacted her personal and financial independence. Spears' decision to seek rehab is seen as a proactive step towards addressing her challenges and regaining control over her life. The journey ahead will likely be closely followed by her fans and the media, given her status as a cultural icon.

Scientists at London's Institute of Cancer Research and the RCSI University of Medicine and Health Sciences in Dublin have announced a new AI-driven approach to identify how patients with advanced bowel cancer will respond to bevacizumab, a drug recently introduced by the NHS. The method uses PhenMap, an AI tool that integrates complex data on the genetic makeup of tumors, allowing researchers to track patterns of how different patients react to the drug. This development aims to spare potentially thousands of patients from being given drugs that would be ineffective in fighting their cancers. In the UK alone, nearly 10,000 cases of advanced bowel cancer are identified every year, with young adults seeing a particular rise in diagnoses. Bowel cancer has the second-highest mortality rate of any cancer, behind only lung cancer. While survival rates can be as high as 98% when caught early, the five-year survival rate for advanced bowel cancer can be as low as 10%. The study tracked 117 European bowel cancer patients who had been treated with chemotherapy and bevacizumab. Researchers identified a group of patients who all had the same gene mutation and were at a high risk of having negative reactions. The scientists behind the tests now hope to expand the number of patient samples and see if the results can be used in treatments for other types of cancer. Anguraj Sadanandam, a professor in stratification and precision medicine at the ICR, said: “Once bowel cancer spreads to other parts of the body, there are very few treatment options available for patients. It is therefore positive that patients can now access the targeted drug bevacizumab on the NHS. However, we know that the majority of patients won’t benefit from the drug, meaning thousands of people in England could be facing unpleasant side effects unnecessarily.” Sadanandam added that while the findings were encouraging, the tool would need to be tested on a larger cohort to be validated. “In future, I hope this approach will lead to a test that can be used by clinicians, to ensure patients receive personalised care that has the highest chance of working against their cancer.”

GSK has revealed promising early results for its treatment for gynaecological cancers, Mocertatug Rezetecan (Mo-Rez), as its chief executive, Luke Miels, seeks to speed up drug development at the group.The company reported that in an early-stage trial, Mo-Rez shrank or eliminated tumours in 62% of patients with ovarian cancer where chemotherapy had failed, and in 67% of those with endometrial cancer.GSK acquired the Mo-Rez cancer treatment, an antibody-drug conjugate (ADC), from China’s Hansoh Pharma in late 2023, and has trialled it in 224 patients around the world, including the UK, over the past year. Few patients needed to stop treatment because of side-effects, the most common being nausea. It is administered every three weeks via intravenous infusion.Combined with data from a separate, intermediate trial in China, these results give GSK the confidence to go straight to late-stage trials, with five clinical studies planned globally in the next few months, including on patients in the UK.Presenting the results at the Society of Gynecologic Oncology’s annual meeting on women’s cancer in Puerto Rico, Hesham Abdullah, GSK’s global head of cancer research and development, said: “Treatment of gynaecological cancers remains a major challenge, with a pressing need for new therapies that offer improved response rates. With Mo-Rez we now have compelling evidence of a promising clinical profile.”Endometrial cancer affects 1.6 million women globally, with 417,000 new cases each year. Ovarian cancer affects 843,000 people, with 240,000 new cases annually.Abdullah described Mo-Rez as a “key asset” in the company’s growing cancer portfolio, expected to be a blockbuster drug with peak annual sales of more than £2bn, which GSK hopes will help it achieve its 2031 sales target of £40bn.

Brazilian President Luiz Inácio Lula da Silva used his Friday social‑media post to herald a new security partnership with the United States as a breakthrough in the fight against transnational crime.The agreement links the Brazilian Federal Revenue Service with U.S. Customs and Border Protection, establishing the DESARMA programme. Under DESARMA the two agencies will exchange real‑time data, apply rigorous cargo‑tracking protocols and launch joint operations to intercept illicit shipments of arms and narcotics.Finance Minister Dario Durigan called the collaboration an “important step in strengthening international cooperation”, noting that it will integrate intelligence and joint actions to curb the flow of weapons and drugs between the two nations.The pact is part of President Donald Trump’s broader “Shield of the Americas” initiative, which seeks to enlist right‑wing governments across the Western Hemisphere in a hard‑line campaign against criminal networks.Despite the cooperation, Lula’s administration has pushed back against Washington’s attempts to label Brazilian gangs such as the Primeiro Comando da Capital (PCC) and Comando Vermelho (CV) as foreign terrorist organisations. Lula and Foreign Minister Mauro Vieira have repeatedly asserted Brazil’s sovereignty and warned against external “tutelage”.In the last twelve months Brazil reported seizing 1,168 illegally imported weapons and parts, most of which originated from the U.S. state of Florida, underscoring the scale of the smuggling problem.A statement from the Revenue Service emphasized that the deal will ensure a “continuous flow of information from U.S. authorities to their Brazilian counterparts”, enhancing operational coordination.Relations remain strained: Vieira told U.S. Secretary of State Marco Rubio that Brazil opposes the terrorist‑label designation, while the Trump administration continues aggressive actions in the region, including lethal strikes on maritime vessels and a controversial raid in Venezuela.Looking ahead, Lula is expected to travel to Washington, D.C., later this year for talks with Trump, providing a diplomatic channel to manage both cooperation and disagreement.

Colombia's Ministry of Commerce, Industry and Tourism announced on Friday that it will increase tariffs on Ecuadorian goods to 100 percent, up from 30 percent. This move is a direct response to Ecuador's decision to impose a 100 percent tariff on Colombian imports a day earlier.The trade dispute between the two South American countries has been escalating, with Ecuador citing a trade deficit and accusing Colombia of not doing enough to combat drug trafficking. However, Colombia has denied these accusations, pointing to its military operations aimed at intercepting illicit drugs, including a significant seizure last November.The diplomatic tensions have also been fueled by disagreements between the two countries' leaders. Ecuador's President Daniel Noboa has clashed with Colombia's President Gustavo Petro over issues including the imprisonment of former Ecuadorian Vice President Jorge Glas, whom Petro has called a political prisoner.Colombian Trade Minister Diana Morales stated that her country had exhausted all diplomatic efforts to resolve the issue with Ecuador. She emphasized that the decision to increase tariffs was made to protect Colombian businesses and communities.

Rehab did not happen to Lena Dunham; she walked into it. The writer describes the moment she entered a stone‑manor facility in the Berkshires, Massachusetts, and was immediately asked to remove her designer shoes and answer mundane questions about her diet, a surreal welcome that felt like a college orientation—except many of the fellow residents struggled with IV heroin. She notes the unsettling blend of patients and staff, all dressed in ordinary clothes, making it impossible to tell who was who. A tattooed man in a Harley‑Davidson shirt turned out to be a sober companion, while a grandmother knitting in slippers battled a severe Benadryl addiction that had once ruined her daughter’s wedding. “Never judge a drug addict by their Patagonia half‑zip fleece,” she writes. Using the pseudonym “Rose O’Neill” – after the pioneering cartoonist – Dunham reflects on feeling trapped in a cycle reminiscent of the late‑career decline of the early 20th‑century artist. It was only after she allowed staff to use her real name that she began to reclaim her identity. Her therapist, Dr. Mark, a kindly man in khakis, asked her to articulate the root causes of her admission. Dunham linked her descent to chronic physical illness, relentless stress from supporting multiple families, hormonal turmoil after a hysterectomy, and a fraught romantic relationship. She also disclosed past sexual trauma, describing the rehab experience as “a fever dream” that echoed those memories. Medication played a paradoxical role. While Klonopin eased anxiety and Percocet dulled pain, the initial IV dose produced a euphoric “shiver through the whole body, better than any orgasm.” She acknowledges the temporary relief as a “pause button” that allowed her racing thoughts to quiet, yet also recognized the danger of dependence. Group sessions revealed complex dynamics. A fellow patient, Walter, breached confidentiality, prompting staff to enforce policy and send him home. The ensuing discussion divided the group, with some defending Walter’s lapse and others demanding accountability. Dunham’s own voice was subdued, emphasizing the tension between personal safety and collective responsibility. In a values‑mapping exercise, Dunham listed ART, FAMILY, MAKING PEOPLE FEEL SEEN as her core priorities, contrasting them with the values of the people she had surrounded herself with during active addiction. This exercise highlighted the stark misalignment between her aspirations and the environment she had inhabited. Despite the strict regimen, Dunham was granted a brief leave to attend the 2018 Met Gala. The decision sparked intense debate among staff about safety, yet she ultimately walked the red carpet, feeling “wan and haunted” amid flashing cameras and champagne she could not enjoy. The experience underscored the surreal juxtaposition of celebrity life and rehab recovery. During the final week, she formally identified as an addict and faced the pivotal question from Dr. Mark: “Do you want to be sober?” The answer marked a turning point, culminating in a moment of pure joy as she ran outdoors, feeling her legs move of their own accord. She closes with a vivid scene of spotting a robin’s egg on the grass, a simple yet profound reminder of life’s unexpected beauty. The memoir Famesick, published by Fourth Estate on 14 April, expands on these revelations and invites readers into the often‑hidden world of addiction behind the celebrity façade.

Ecuador's government, led by President Daniel Noboa, has imposed 100% tariffs on imports from Colombia, effective May 1. This decision comes as a response to what Ecuador sees as Colombia's inadequate efforts to combat drug trafficking and improve border security.The move is the latest escalation in a months-long feud between the right-wing Noboa and his left-wing counterpart in Colombia, Gustavo Petro. Ecuador's Ministry of Production justified the tariff hike as a necessary measure to confront drug trafficking on the border and protect its citizens and territory.This is not the first tariff imposed by Ecuador on Colombian goods. Previously, Ecuador had slapped 50% tariffs on Colombian exports as of March, which was a spike from a 30% tariff rate announced in January. Colombia has responded by suspending cross-border energy sales and imposing retaliatory tariffs on certain Ecuadorian products.The tensions between Ecuador and Colombia are further complicated by Petro's 'Total Peace' policy, which involves negotiations with rebel groups and criminal networks. This approach has been met with criticism from right-wing leaders like Noboa and US President Donald Trump, who have accused Petro of not doing enough to tackle drug trafficking.The situation has also been influenced by US-Colombia relations, with the Trump administration decertifying Colombia as an ally in its 'war on drugs' and sanctioning Petro and his family. Noboa has echoed Trump's stance on several foreign policy issues, including pressure on left-wing governments in the region.